2023-11-02T16:43:31-05:00 2022-12-31 841158905 CAUSEY DEMGEN & MOORE PC 1099 18TH ST STE 2300 DENVER CO 802021939 990 2022-01-01 200499338 INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER INTE 7203252948 999 17TH ST STE 200 DENVER CO 802022725 JOHN SKADOW CFO 7203252948 2023-11-02 1 JOHN SKADOW 999009999 1 LAUREN J STOLZ P01432391 3032962229 2023-10-31 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z JOHN SKADOW 999 17TH ST SUITE 200 DENVER CO 802022725 17603769 0 X WWW.IASLC.ORG X 2003 CO TO PROMOTE THE STUDY OF THE ETIOLOGY, EPIDEMIOLOGY, PREVENTION, DIAGNOSIS, TREATMENT AND ALL OTHER ASPECTS OF LUNG CANCER AND OTHER THORACIC MALIGNANCIES.TO PROVIDE EDUCATION AND INFORMATION ABOUT LUNG CANCER AND OTHER THORACIC MALIGNANCIES TO IASLC MEMBERS, TO THE MEDICAL COMMUNITY AT LARGE, AND TO THE PUBLIC.TO USE ALL AVAILABLE MEANS TO ELIMINATE LUNG CANCER AND OTHER THORACIC MALIGNANCIES AS A HEALTH THREAT FOR THE INDIVIDUAL PATIENT AND THROUGHOUT THE WORLD. 15 15 35 0 0 0 2374814 790597 12626237 16694390 -1253020 -5842161 -62718 -91446 13685313 11551380 0 0 0 0 3875713 3497288 0 0 533630 7878329 11130541 11754042 14627829 1931271 -3076449 23299078 25381895 6092120 10197977 17206958 15183918 X TO PROMOTE THE STUDY OF THE ETIOLOGY, EPIDEMIOLOGY, PREVENTION, DIAGNOSIS, TREATMENT AND ALL OTHER ASPECTS OF LUNG CANCER AND OTHER THORACIC MALIGNANCIES.TO PROVIDE EDUCATION AND INFORMATION ABOUT LUNG CANCER AND OTHER THORACIC MALIGNANCIES TO IASLC MEMBERS, TO THE MEDICAL COMMUNITY AT LARGE, AND TO THE PUBLIC.TO USE ALL AVAILABLE MEANS TO ELIMINATE LUNG CANCER AND OTHER THORACIC MALIGNANCIES AS A HEALTH THREAT FOR THE INDIVIDUAL PATIENT AND THROUGHOUT THE WORLD. 0 0 1008602 0 0 MEMBERSHIPS AND OTHER PROGRAMS TO ADVANCE THE STUDY OF LUNG CANCER 3146193 0 1717068 PUBLICATIONS AND SCIENTIFIC PROGRAMS TO PROVIDE EDUCATION TO THE WORLD WIDE LUNG CANCER COMMUNITY REGARDING THE LATEST ADVANCES IN LUNG CANCER TREATMENT. 7805094 0 3422706 MEETING AND WEB SEMINARS TO DISSEMINATE INFORMATION REGARDING THE LATEST ADVANCES IN LUNG CANCER TREATMENT. 11959889 1 1 0 0 0 0 0 0 0 0 1 1 0 0 1 1 1 0 0 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 32 0 1 35 1 0 0 0 0 0 0 0 0 0 0 X 15 15 0 0 0 0 1 1 0 1 1 0 0 0 1 1 1 0 0 1 1 0 CO X JOHN SKADOW CFO 7203252948 999 17TH STREET SUITE 200 DENVER CO 802022725 HEATHER WAKELEE MD PRESIDENT 10.00 X 0 0 0 ERIK THUNNISSEN MD TREASURER 10.00 X 0 0 0 TETSUYA MITSUDOMI MD PHD PAST PRESIDENT 10.00 X 0 0 0 PAUL VAN SCHIL MD PRESIDENT ELECT 10.00 X 0 0 0 YOUNG TAE KIM MD PHD DIRECTOR 3.00 X 0 0 0 JOACHIM AERTS MD PHD DIRECTOR 3.00 X 0 0 0 ROY HERBST MD DIRECTOR 3.00 X 0 0 0 ANDREA BEZJAK MD SECRETARY 3.00 X 0 0 0 MORTEN QUIST PHD DIRECTOR 3.00 X 0 0 0 CARLOS GIL FERREIRA MD PHD DIRECTOR 3.00 X 0 0 0 JHANELLE GRAY MD DIRECTOR 3.00 X 0 0 0 CAICUN ZHOU PHD DIRECTOR 3.00 X 0 0 0 LECIA VANDAM SEQUIST MD MPH DIRECTOR 3.00 X 0 0 0 MING-SOUND TSAO MD FRCPC DIRECTOR 3.00 X 0 0 0 PAULA UGALDE MD DIRECTOR 3.00 X 0 0 0 KAREN L KELLY CEO 40.00 X 332435 0 37118 JOHN SKADOW CFO 40.00 X 207401 0 46233 MURRY WYNES DIRECTOR OF SCIENTIFIC AFF 40.00 X 200847 0 31122 MATTHEW C YEINGST CHIEF DEVELOPMENT OFFICER 34.00 X 184040 0 44559 REBECCA BUNN SENIOR ADVISOR SCIENTIFIC 40.00 X 136348 0 29170 KATHLEEN M DOHERTY DIRECTOR, HR 40.00 X 133846 0 24157 KRISTIN RICHEIMER FORMER INTERIM CEO 40.00 X 193216 0 18489 1388133 0 230848 11 1 1 0 INTERNATIONAL CONFERENCE SERVICES 1201 W PENDER ST STE 300 VANCOUVER BC CA CONFERENCE MANAGEMENT FEES & OTHER 3855206 CANCER RESEARCH & BIOSTATISTICS 1505 WESTLAKE AVENUE N STE 750 SEATTLE WA 98109 STAGING PROJECT LABOR, SUPPLIES & OTHER 1010129 REED MESSE WIEN GMBH MESSEPLATZ 1 1020 WIEN AU CONFERENCE VENUE 480036 999 OFFICE LLC PO BOX 846850 LOS ANGELES CA 90084 RENT EXPENSES AND PARKING 403013 ELSEVIER 2100 MILVIA STREET SUITE 300 BERKLEY CA 94704 JTO PUBLISHER 282054 5 667983 122614 790597 MEETING INCOME 541900 13462619 3422706 10039913 PUBLICATIONS 541900 1761108 583405 1177703 SCIENTIFIC PROJECTS 541900 1452703 1133663 319040 WEB SEMINARS 541900 17960 17960 16694390 210228 210228 8672 0 8672 8672 8672 2584048 3468341 -2584048 -3468341 -6052389 -6052389 FOREIGN CURRENCY GAIN 523000 -100118 -100118 -100118 11551380 5139774 0 5621009 539836 539836 2957452 1725092 848281 384079 24508 24508 49350 49350 462981 220921 218798 23262 331926 243746 41874 46306 205185 101609 94310 9266 134715 97222 26621 10872 6719850 6719850 355905 285054 50578 20273 SCIENTIFIC PROGRAMS 2110711 2110711 OTHER PROGRAMS 423502 330812 58159 34531 BOARD MEETINGS 135348 135348 COMMUNICATION 56470 39896 11533 5041 120090 84976 35114 14627829 11959889 2134310 533630 6038922 623432 7842263 4175676 4783308 1514332 1875986 1942455 995283 1562578 947172 10007570 8178483 0 1131251 23299078 25381895 1937626 1397094 4154494 7842263 0 958620 6092120 10197977 X 17206958 15183918 17206958 15183918 23299078 25381895 -3076449 1065506 0 X X 0 1 X 1 0 X 763425 836129 632870 1823612 790597 4846633 13551881 16912007 6081094 12338079 16694390 65577451 14315306 17748136 6713964 14161691 17484987 70424084 0 0 0 70424084 -292863 1057314 -21648 168645 218900 1130348 -292863 1057314 -21648 168645 218900 1130348 14022443 18805450 6692316 14330336 17703887 71554432 0.98420 0.98160 0.01580 0.01840 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 882019 346507 535512 531532 296280 235252 528904 352496 176408 947172 OTHER SECURITIES 8178483 F 8178483 RIGHT OF USE LIABILITY-NONCURRENT 958620 958620 X 16890050 1065506 4273164 5338670 11551380 0 11551380 16127903 1523092 1523092 14604811 35115 35115 14639926 PART X, LINE 2: THE ASSOCIATION HAS ADOPTED GUIDANCE ON ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES. AFTER EVALUATING THE TAX POSITIONS TAKEN, NONE ARE CONSIDERED TO BE UNCERTAIN; THEREFORE, NO AMOUNTS HAVE BEEN RECOGNIZED AS OF DECEMBER 31, 2021 AND 2022. THE ASSOCIATION IS NO LONGER SUBJECT TO U.S. FEDERAL INCOME TAX EXAMINATIONS FOR YEARS PRIOR TO 2018. SCHEDULE D PART XII LINE 4B THE ASSOCIATION ELECTED TO ADOPT ASU 2021-09 LEASES (TOPIC 842) EFFECTIVE JANUARY 1, 2022, UTILIZING AN OPTIONAL TRANSITION METHOD, WHICH ALLOWED RECOGNITION OF A CUMULATIVE EFFECT ADJUSTMENT TO THE OPENING BALANCE OF NET ASSETS. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES SCIENTIFIC CONFERENCE 4435756 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES SCIENTIFIC CONFERENCE 500000 0 0 0 0 0 0 4935756 0 4935756 0 0 0 0 0 0 PART I, LINE 2: 1. GRANTS WILL BE INITIALLY REVIEWED BY THE COMMITTEE CHAIR FOR COMPLETENESS. INCOMPLETE SUBMISSIONS OR GRANTS SUBMITTED AFTER THE DEADLINE WILL BE RETURNED TO THE PI IN 48 HOURS. 2. EACH MEMBER OF THE SCIENTIFIC REVIEW COMMITTEE WILL RIGOROUSLY REVIEW THE APPLICATIONS. APPLICATIONS WILL BE SCORED ON FOUR CRITERIA: A. POTENTIAL OF THE CANDIDATE: IS THE CANDIDATE COMMITTED TO A CAREER IN LUNG CANCER RESEARCH? DOES THE CANDIDATE HAVE BASIC TRAINING RELATED TO THE PROJECT PROPOSED? PUBLISHED/SUBMITTED PAPERS OR ABSTRACTS CURRENT OR PENDING GRANT SUBMISSIONS STRONG LETTERS OF SUPPORT B. SCIENTIFIC MERIT OF THE PROJECT: IS THE PROPOSAL ORIGINAL? IS THE PROPOSAL CLEAR & CONCISE? ARE THE SPECIFIC AIMS REASONABLE? IS THE METHODOLOGY REASONABLE TO ACCOMPLISH THE OBJECTIVES? CAN THE PROJECT BY COMPLETED IN THE 2 YEAR TIME FRAME? C. SIGNIFICANCE OF PROJECT: IS THE PROJECT WITHIN THE IASLC SCOPE? WHAT WILL THIS INFORMATION CONTRIBUTE TO KNOWLEDGE IN THIS FIELD? DO THESE RESULTS SIGNIFICANTLY IMPROVE THE APPLICATION OF KNOWLEDGE OF LUNG CANCER? WILL THESE DATA STIMULATE FURTHER SCIENTIFIC RESEARCH INTO LUNG CANCER? D. STRENGTH OF THE PI/INSTITUTIONAL SUPPORT (FOR FELLOWSHIP GRANTS): IS THE PI DEDICATED TO ASSISTING IN THE EXECUTION AND COMPLETION OF THE PROJECT? IS THE PI OF GOOD STANDING IN THE FIELD OF LUNG CANCER RESEARCH? DOES THE PI HAVE SUFFICIENT GRANT SUPPORT FOR THE FELLOW TO COMPLETE THE PROJECT IF REQUIRED? DOES THE INSTITUTION HAVE THE NECESSARY RESOURCES TO SUPPORT THE PROJECT? SCORES WILL RANGE FROM 1-5. 5 - OUTSTANDING 4 - EXCELLENT 3 - GOOD 2 - POOR 1 - UNACCEPTABLE TOTAL SCORES WILL THEN BE TABULATED, AVERAGED, AND THE CANDIDATE RANKED. THE COMMITTEE WILL MEET BY CONFERENCE CALL TO SELECT THE AWARDEES. 3. PROGRESS REPORTS FROM YEAR 1 WILL BE REVIEWED BY THE COMMITTEE CHAIR. PART III ACCOUNTING METHOD: 1 1 X X X 1 0 0 0 0 0 0 0 0 KAREN L KELLY CEO 332435 0 0 0 0 0 28940 0 8178 0 369553 0 0 0 JOHN SKADOW CFO 199401 0 8000 0 0 0 20536 0 25697 0 253634 0 0 0 MURRY WYNES DIRECTOR OF SCIENTIFIC AFF 198347 0 2500 0 0 0 19881 0 11241 0 231969 0 0 0 MATTHEW C YEINGST CHIEF DEVELOPMENT OFFICER 182040 0 2000 0 0 0 18200 0 26359 0 228599 0 0 0 KRISTIN RICHEIMER FORMER INTERIM CEO 188216 0 5000 0 0 0 14374 0 4115 0 211705 0 0 0 REBECCA BUNN SENIOR ADVISOR SCIENTIFIC 133348 0 3000 0 0 0 11446 0 17724 0 165518 0 0 0 KATHLEEN M DOHERTY DIRECTOR, HR 127346 0 6500 0 0 0 13181 0 10976 0 158003 0 0 0 PART I, LINE 4A INTERIM CEO - KRISTIN RICHEIMER - $48,217 FORM 990, PART VI, SECTION A, LINE 6 MEMBER QUALIFICATIONS. MEMBERS MUST BE INDIVIDUALS. MEMBERS SHOULD BE DEDICATED TO THE FIGHT AGAINST LUNG CANCER AND OTHER THORACIC MALIGNANCIES. SUCH DEDICATION CAN BE DUE TO THE MEMBER'S STATUS AS A CLINICIAN, RESEARCHER, SURGEON OR OTHER MEMBER OF THE LUNG CANCER MEDICAL OR RESEARCH PROFESSION, INCLUDING, BUT NOT LIMITED TO MDS, PHDS, NURSES, PHARMACISTS, STATISTICIANS, RESPIRATORY THERAPISTS, PATIENT ADVOCATES AND ALL OTHERS INTERESTED IN LUNG CANCER AND OTHER THORACIC MALIGNANCIES. ADDITIONALLY, MEMBERS MAY BE PATIENTS AND SURVIVORS OF LUNG CANCER AND OTHER THORACIC MALIGNANCIES, AND THEIR CARE GIVERS. MEMBERS MAY NOT ENGAGE IN AN ACTION OR POSITION OR HAVE AN INTEREST THAT IS CONTRARY TO THE ASSOCIATION'S PRINCIPLES, AS DETERMINED BY THE BOARD OF DIRECTORS IN ITS SOLE AND ABSOLUTE DISCRETION. MEMBERS ARE ADMITTED BY THE BOARD OF DIRECTORS UPON APPLICATION TO ASSOCIATION, IN ITS SOLE AND ABSOLUTE DISCRETION. THE BOARD OF DIRECTORS MAY ESTABLISH AND CHANGE MEMBERSHIP CRITERIA, FROM TIME-TO-TIME. MEMBER STATUS IS NONTRANSFERABLE. FORM 990, PART VI, SECTION A, LINE 7A ALL DIRECTORS, OTHER THAN THOSE DIRECTORS APPOINTED BY THE BOARD OF DIRECTORS TO FILL A VACANCY RESULTING FROM CAUSES OTHER THAN AN INCREASE IN THE SIZE OF THE BOARD OF DIRECTORS, SHALL BE ELECTED BY THE VOTING MEMBERS FROM AMONG THE CANDIDATES WHO HAVE BEEN NOMINATED BY THE NOMINATING COMMITTEE, SUBJECT TO THE REVIEW AND APPROVAL OF THE BOARD OF DIRECTORS, NO LATER THAN NINETY (90) DAYS PRIOR TO THE ASSOCIATION WORLD CONFERENCE FORM 990, PART VI, SECTION B, LINE 11B FOR 2022, THE CEO & CFO WILL REVIEW THE RETURN PRIOR TO THE FILING OF FORM 990. THE TAX RETURN WILL BE AVAILABLE TO THE BOARD AND FINANCE COMMITTEE FOR REVIEW FOLLOWING THE FILING OF FORM 990. FORM 990, PART VI, SECTION B, LINE 12C THROUGH YEARLY REVIEWS FORM 990, PART VI, SECTION B, LINE 15 THROUGH YEARLY REVIEWS FORM 990, PART VI, SECTION C, LINE 19 AVAILABLE UPON REQUEST PART XII, LINE 2C NO CHANGES TO PROCEDURES IN CURRENT YEAR THE EARLY LUNG IMAGING CONFEDERATION (ELIC) 999 17TH STREET SUITE 200 DENVER CO 802022725 833783832 RESEARCH INITIATIVE FOR LUNG IMAGING CO 43024 224811 INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER IASLC FOUNDATION LLC 999 17TH STREET SUITE 200 DENVER CO 802022725 921080412 SUPPORT LUNG CANCER EDUCATION/RESEARCH CO 0 0 INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER INTERNATIONAL LUNG CANCER FOUNDATION 999 17TH STREET SUITE 200 DENVER CO 802022725 843360404 SUPPORT LUNG CANCER EDUCATION/RESEARCH CO 501(C)(3) LINE 10 INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 INTERNATIONAL LUNG CANCER FOUNDATION N 8672 ALLOCATION OF SQUARE FOOTAGE/TIME INTERNATIONAL LUNG CANCER FOUNDATION O 94919 ALLOCATION OF HOURLY WAGES